NPPB and AL amyloidosis: In patients with multiple myeloma receiving proteasome inhibitors, baseline high levels of BNP (>100 pg/mL) and NT-proBNP (>125 pg/mL) predicted cardiovascular adverse events associated with worse overall outcomes [89].